bioXXmed Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

bioXXmed has a total shareholder equity of €107.9K and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €279.4K and €171.5K respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranın/a
Nakit€87.48k
Eşitlik€107.87k
Toplam yükümlülükler€171.54k
Toplam varlıklar€279.41k

Son finansal sağlık güncellemeleri

Recent updates

Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

Jul 29
Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

CytoTools AG (ETR:T5O): Are Analysts Optimistic?

May 12
CytoTools AG (ETR:T5O): Are Analysts Optimistic?

Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

Jan 08
Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: T5O's short term assets (€237.0K) exceed its short term liabilities (€130.0K).

Uzun Vadeli Yükümlülükler: T5O's short term assets (€237.0K) exceed its long term liabilities (€41.6K).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: T5O is debt free.

Borcun Azaltılması: T5O has no debt compared to 5 years ago when its debt to equity ratio was 14.5%.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Insufficient data to determine if T5O has enough cash runway based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if T5O has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Sağlıklı şirketleri keşfedin